摘要
目的探讨蔗糖铁注射液治疗血液透析患者肾性贫血的疗效与安全性。方法 30例维持性血液透析患者分为治疗组(蔗糖铁组)与对照组(右旋糖酐铁组),每组各15例。将100mg蔗糖铁和100mg右旋糖酐铁分别稀释于100ml生理盐水中,于每次血透时使用。每周治疗2次,治疗时间为5周,观察时间共8周。两组患者的总补铁量均为1000mg。全部病例都合并使用红细胞生成素(EPo)治疗。观察并比较两组患者治疗贫血的效果、铁代谢指标变化及不良反应发生情况。结果治疗组与对照组的Hb均较治疗前显著升高,两组间差异无统计学意义。治疗后两组铁蛋白和转铁蛋白饱和度均明显高于治疗前,两组间差异无统计学意义。两组患者血清BUN、Scr、ALT和AST等均无明显变化。两组患者均无严重不良反应发生,对照组有1例表现为轻度寒战。结论蔗糖铁注射液是治疗血液透析患者肾性贫血的一种安全有效的药物。
Objective To explore the safety and efficacy of intravenous iron sucrose in treatment of kidney of anemic hemodialysis patients.Methods Thirty hemodialysis patients were divided into two groups： treatment group（iron sucrose group,n=15） and control group（iron dextran group,n=15）.The patients were treated with iron sucrose or iron dextran,100 mg intravenous,during hemodialysis sessions.The duration of follow-up was eight weeks.The total supplement iron amount of both groups was 1000 mg.Erythropoietin（EPO） was used.The safety and efficacy were assessed by evaluating the changes in Hb,Hct,ferritin,transferring,transferring saturation and side effects in both groups pre-and post-treatment.Results The Hb levels and Hct levels in both groups significantly increased（P0.05） at post-treatment.The levels of ferritin and transferring saturation increased significantly in both groups.There were no obvious changes in BUN,Scr,ALT and AST.There were no severe adverse events in both groups and 1 case suffered from shivering in the dextran group.Conclusions Intravenous iron sucrose is effective and safe in treating anemic hemodialysis patients.
出处
《医药论坛杂志》
2011年第20期30-32,共3页
Journal of Medical Forum
关键词
蔗糖铁注射液
血液透析
肾性贫血
Intravenous iron sucrose
Hemodialysis
Kidney aonemic
